MHRA Explains Its Approach To New 'Safety Features' In 2019
Executive Summary
The MHRA has set out its position on those aspects of the new “safety feature” rules for prescription drugs where member states have flexibility to choose their options, such as the information to be included in the “unique identifier” and the conditions for “checking out” medicines from the verification system. The European Medicines Verification System is being introduced as part of the EU Falsified Medicines Directive.
You may also be interested in...
Europe’s Medicines Verification System Prepares To Go Live
Europe’s ambitious new system for verifying the authenticity of prescription medicines circulating on the market is about to come into operation.
New UK Drug Assessment Routes Among Latest Measures For No-Deal Brexit
The UK MHRA has updated its guidance on how it plans to regulate medicines and healthcare products if the UK leaves the EU without a deal. Among many other things, it includes the promise of free scientific advice for SMEs and details on how marketing applications for centrally authorized products will be converted into UK ones in the event of a hard Brexit.
UK MHRA Outlines 'Safety Feature' Challenges Facing Wholesale Sector
At a recent MHRA symposium, wholesalers were treated to a presentation on possible hurdles they may encounter as the EU Falsified Medicines Directive brings in a new product verification system from February next year.